Therapy Areas: Oncology
Antengene's ATG-101 clinical trial application receives Australian regulatory approval
22 July 2021 -

Antengene Corporation Limited (SEHK: 6996.HK), a China-based biopharmaceutical company involved in discovering, developing and commercialising therapeutics in haematology and oncology, announced on Thursday that it has received approval from Bellberry Human Research Ethics Committee (HREC) in Australia for its clinical trial application for the phase one trial of ATG-101 in patients with metastatic/advanced solid tumours and B-cell non-Hodgkin's lymphoma.

The move is claimed to represent an important milestone for the company as ATG-101 is the in-house developed innovative molecule with global rights entering clinical stage. The multi-centre open-label, Phase I trial is aimed at assessing the safety and tolerability of the product as a single agent in patients with advanced solid tumours and non-Hodgkin's lymphoma.

The company said that the product is the first PD-L1/4-1BB bispecific antibody entering clinical stage in Australia.



Related Headlines